Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages e170-e177

  Jacobson, Robert M ^a   Jackson, Lisa A ^a   Reisinger, Keith ^a   Izu, Allen ^a   Odrljin, Tatjana ^a   Dull, Peter M ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Antibody persistence; Booster response; Conjugate vaccine; Meningococcal vaccine; Polysaccharide vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; MALE; PRIORITY JOURNAL; SERUM BACTERICIDAL ANTIBODY ASSAY; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84876280696     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318279ac38     Document Type: Article

References (21)

1. Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin. 2011;7:170-182
2. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-191
3. Bröker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis. 2010;8:47-50
4. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28:86-91
5. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299:173-184
6. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4:156-167
7. Jódar L, Griffiths E, Feavers I. Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine. 2004;22:1047-1053
8. Grizzle JE, Starmer CF, Koch GG. Analysis of categorical data by linear models. Biometrics. 1969;25:489-504
9. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60:72-76
10. Lepow ML, Goldschneider I, Gold R, et al. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics. 1977;60:673-680
11. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;2:114-118
12. Rashid H, Booy R, Shafi S, et al. Conjugate versus polysaccharide meningococcal vaccine. Lancet Infect Dis. 2008;8:215
13. Gill CJ, Baxter R, Anemona A, et al. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin. 2010;6:881-887
14. Black S, Klein NP, Shah J, et al. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine. 2010;28:657-663
15. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun. 2009;77:764-769
16. Santos GF, Deck RR, Donnelly J, et al. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8:616-623
17. Gill CJ, Ram S, Welsch JA, et al. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine. 2011;30:29-34
18. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307-1326
19. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23:2222-2227
20. Nimenrix summary of product characteristics (SPC). Electronic Medicines Compendium (eMC) Web site. Available at: http://www.medicines.org.uk/EMC/medicine/26514/SPC/Nimenrix/#CLINICAL_PARTS. Accessed September 13, 2012
21. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev. 2005:CD001093